The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra, Larisa Greenberg, Charles E. Geyer

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalCurrent oncology reports
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The emerging role of lapatinib in HER2-positive breast cancer'. Together they form a unique fingerprint.

  • Cite this